Printer Friendly

MARION MERRELL DOW RECEIVES CLEARANCE TO MARKET ONCE-DAILY CARDIZEM CD FOR ANGINA

 MARION MERRELL DOW RECEIVES CLEARANCE TO MARKET
 ONCE-DAILY CARDIZEM CD FOR ANGINA
 KANSAS CITY, Mo., Oct. 15 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today received clearance to market Cardizem(R) CD (diltiazem HCl) once-a-day capsules for treating angina, a condition that causes chest pain due to insufficient blood flow to the heart.
 Cardizem CD was first marketed in December 1991 for the treatment of high blood pressure, and, with the new expanded indication for treating angina, becomes available for physicians' use in treating both angina and hypertension on a once-daily basis.
 One of the largest selling cardiovascular brands in the United States and Canada, the Cardizem(R) brand accounted for more than $900 million in sales in 1991.
 "The addition of the angina indication will greatly strengthen the Cardizem brand," said Fred W. Lyons, Jr., president and chief executive officer. "And most importantly, it will provide a more convenient and less expensive form of Cardizem for angina patients."
 Once-a-day dosages of medications are considered important because they are easier for patients to use and to take consistently. Currently, Cardizem CD is available in 120 mg, 180 mg, 240 mg and 300 mg capsules.
 Cardizem belongs to a class of drugs known as calcium channel blockers. It works in angina caused by coronary artery spasm by relaxing and opening the coronary arteries.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide. In 1991, Marion Merrell Dow had sales of $2.85 billion and invested nearly $400 million in Research and Development.
 -0- 10/15/92
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:


BB -- DV014 -- 0669 10/15/92 17:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1992
Words:313
Previous Article:SIMON & SCHUSTER FIRST PUBLISHER TO PROCESS ORDER ENTRY TRANSACTIONS VIA TOUCHTONE PHONE
Next Article:PICTURETEL CORPORATION ANNOUNCES THIRD QUARTER REVENUE INCREASE OF 63 PERCENT; RESULTS PROVE STRONGER THAN EXPECTED
Topics:


Related Articles
MARION MERRELL DOW ANNOUNCES SETTLEMENT WITH GENERIC MAKER ON LOOK-ALIKE TABLETS
CARDIZEM(R) CD, ONCE-A-DAY HIGH BLOOD PRESSURE MEDICATION RELEASED FOR U.S MARKETING
MARION MERRELL DOW REPORTS 16 PERCENT GAIN IN THIRD-QUARTER EARNINGS PER SHARE
MARION MERRELL DOW LAUNCHES NICOTINE PATCH AS A NONPRESCRIPTION AID IN THE UNITED KINGDOM
MARION MERRELL DOW AND TANABE SEIYAKU CO. FILE PATENT SUITS AGAINST CARDIZEM IMITATORS
MARION MERRELL DOW & TANABE SEIYAKU
MARION MERRELL DOW FILES SUIT OVER COMPETITOR'S CLAIMS THAT DRUGS ARE SIMILAR
MARION MERRELL DOW AND TANABE SEIYAKU FILE INTERNATIONAL TRADE COMPLAINT AGAINST CARDIZEM IMITATORS
MARION MERRELLL DOW ANNOUNCES CARDIZEM CD APPROVAL IN CANADA FOR TREATMENT OF ANGINA
DILTIAZEM PATENT PROCESS CONFIRMED -- CLEARS WAY FOR MARION MERRELL DOW CASE AT INTERNATIONAL TRADE COMMISSION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters